Disordered growth hormone secretion in fibromyalgia: A review of recent findings and a hypothesized etiology

Robert (Rob) Bennett

    Research output: Contribution to journalArticle

    40 Citations (Scopus)

    Abstract

    Growth hormone (GH) deficiency occurs in about 30% of fibromyalgia patients. Treatment of GH deficient fibromyalgia patients with recombinant growth hormone improves several clinical features, including the tender point count. Defective GH secretion in these patients appears to be due to increased somatostatin tone in the hypothalamus. An hypothesis is presented which relates dysfunctional GH secretion to the effects of intermittent hypercortisolemia on upregulating the density of β-adrenergic receptors in the hypothalamus. The resulting augmentation of β-adrenergic tone stimulates the release of somatostatin, thus, impairing GH secretion.

    Original languageEnglish (US)
    Pages (from-to)72-76
    Number of pages5
    JournalZeitschrift fur Rheumatologie
    Volume57
    Issue numberSUPPL. 2
    StatePublished - 1998

    Fingerprint

    Fibromyalgia
    Growth Hormone
    Somatostatin
    Hypothalamus
    Adrenergic Agents
    Adrenergic Receptors

    Keywords

    • Fibromyalgia
    • GH deficiency
    • GH treatment
    • Growth hormone
    • IGF-1
    • Somatostatin

    ASJC Scopus subject areas

    • Rheumatology

    Cite this

    Disordered growth hormone secretion in fibromyalgia : A review of recent findings and a hypothesized etiology. / Bennett, Robert (Rob).

    In: Zeitschrift fur Rheumatologie, Vol. 57, No. SUPPL. 2, 1998, p. 72-76.

    Research output: Contribution to journalArticle

    @article{a3b677ce8c3046929ec82622b2498708,
    title = "Disordered growth hormone secretion in fibromyalgia: A review of recent findings and a hypothesized etiology",
    abstract = "Growth hormone (GH) deficiency occurs in about 30{\%} of fibromyalgia patients. Treatment of GH deficient fibromyalgia patients with recombinant growth hormone improves several clinical features, including the tender point count. Defective GH secretion in these patients appears to be due to increased somatostatin tone in the hypothalamus. An hypothesis is presented which relates dysfunctional GH secretion to the effects of intermittent hypercortisolemia on upregulating the density of β-adrenergic receptors in the hypothalamus. The resulting augmentation of β-adrenergic tone stimulates the release of somatostatin, thus, impairing GH secretion.",
    keywords = "Fibromyalgia, GH deficiency, GH treatment, Growth hormone, IGF-1, Somatostatin",
    author = "Bennett, {Robert (Rob)}",
    year = "1998",
    language = "English (US)",
    volume = "57",
    pages = "72--76",
    journal = "Zeitschrift fur Rheumatologie",
    issn = "0340-1855",
    publisher = "D. Steinkopff-Verlag",
    number = "SUPPL. 2",

    }

    TY - JOUR

    T1 - Disordered growth hormone secretion in fibromyalgia

    T2 - A review of recent findings and a hypothesized etiology

    AU - Bennett, Robert (Rob)

    PY - 1998

    Y1 - 1998

    N2 - Growth hormone (GH) deficiency occurs in about 30% of fibromyalgia patients. Treatment of GH deficient fibromyalgia patients with recombinant growth hormone improves several clinical features, including the tender point count. Defective GH secretion in these patients appears to be due to increased somatostatin tone in the hypothalamus. An hypothesis is presented which relates dysfunctional GH secretion to the effects of intermittent hypercortisolemia on upregulating the density of β-adrenergic receptors in the hypothalamus. The resulting augmentation of β-adrenergic tone stimulates the release of somatostatin, thus, impairing GH secretion.

    AB - Growth hormone (GH) deficiency occurs in about 30% of fibromyalgia patients. Treatment of GH deficient fibromyalgia patients with recombinant growth hormone improves several clinical features, including the tender point count. Defective GH secretion in these patients appears to be due to increased somatostatin tone in the hypothalamus. An hypothesis is presented which relates dysfunctional GH secretion to the effects of intermittent hypercortisolemia on upregulating the density of β-adrenergic receptors in the hypothalamus. The resulting augmentation of β-adrenergic tone stimulates the release of somatostatin, thus, impairing GH secretion.

    KW - Fibromyalgia

    KW - GH deficiency

    KW - GH treatment

    KW - Growth hormone

    KW - IGF-1

    KW - Somatostatin

    UR - http://www.scopus.com/inward/record.url?scp=0032441567&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=0032441567&partnerID=8YFLogxK

    M3 - Article

    C2 - 10025088

    AN - SCOPUS:0032441567

    VL - 57

    SP - 72

    EP - 76

    JO - Zeitschrift fur Rheumatologie

    JF - Zeitschrift fur Rheumatologie

    SN - 0340-1855

    IS - SUPPL. 2

    ER -